Arcutis Biotherapeutics announced the appointment of Christopher Peetz, CEO of Mirum Pharmaceuticals, to its Board of Directors effective July 15, 2026. Peetz brings extensive biopharmaceutical leadership experience from roles at multiple companies including Onyx Pharmaceuticals and Tobira. The appointment comes as Arcutis continues to expand its ZORYVE (roflumilast) franchise for treating inflammatory skin diseases and evaluates pipeline expansion through strategic acquisitions.

The FDA has approved ZORYVE cream 0.3% for treating plaque psoriasis in children as young as age 2, marking the first once-daily, non-steroidal therapy for this indication. This is Arcutis' seventh FDA approval for ZORYVE in four years. The approval addresses a significant treatment gap for young children with plaque psoriasis, offering a steroid-free option suitable for use anywhere on the body with no duration restrictions.

Arcutis Biotherapeutics director Sue-Jean Lin sold 4,946 shares worth $121,000 on June 15, 2026, under a pre-arranged trading plan. The sale reduced her stake by 15% but she retains over 27,500 shares. The insider transaction appears routine amid strong company performance, with ZORYVE revenue climbing 65% year-over-year to $105.4 million in Q1, and the company narrowing quarterly losses while maintaining positive cash flow.

Antag Therapeutics announced the election of Keith Leonard as Chairman of its Board of Directors. Leonard brings 30 years of biopharmaceutical industry experience, including previous roles as Chairman and CEO of Unity Biotechnology and co-founder/CEO of Kythera Biopharmaceuticals. The appointment comes as Antag prepares to initiate Phase 2a trials of AT7687, its lead GIPR antagonist candidate for obesity treatment.

Arcutis Biotherapeutics granted an aggregate of 44,000 restricted stock units to six newly hired employees as a material inducement for employment. The RSUs vest over four years with 25% vesting annually, subject to continuous employment. The grants were approved by the Compensation Committee under the company's 2022 Inducement Plan.

Arcutis Biotherapeutics announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, in Miami. The commercial-stage biopharmaceutical company, focused on immuno-dermatology innovations, will participate in a fireside chat. The company also reported first quarter 2026 financial results and provided a business update.

Arcutis Biotherapeutics granted 269,000 restricted stock units and options for 70,000 shares to 40 newly hired employees as inducement awards. The company also submitted a supplemental New Drug Application to the FDA to expand ZORYVE cream's indication to treat atopic dermatitis in infants as young as 3 months, supported by Phase 2 study data.

Arcutis Biotherapeutics reported Q1 2026 net product revenue of $105.4 million for ZORYVE (roflumilast), representing 65% year-over-year growth despite 17% sequential decline due to typical Q1 seasonality. The company submitted a supplemental New Drug Application to expand ZORYVE cream 0.05% for treating atopic dermatitis in infants ages 3-24 months, completed enrollment in a foam formulation trial for pediatric psoriasis, and initiated a Phase 1 study for investigational ARQ-234. The company maintained positive operating cash flow of $2.2 million and reaffirmed full-year 2026 revenue guidance of $480-495 million.

Arcutis Biotherapeutics announced it will report first quarter 2026 financial results on May 6, 2026, followed by a conference call at 4:30pm ET. The company also presented new Phase 2 results in infants with atopic dermatitis at the 2026 American Academy of Dermatology Annual Meeting and will present at the 25th Annual Needham Virtual Healthcare Conference.

Arcutis Biotherapeutics director Howard G. Welgus sold 10,000 shares worth $239,000 on April 1, 2026, under a pre-planned 10b5-1 trading plan adopted in March 2025. The sale represents a routine liquidity event rather than a loss of confidence, as the company's stock has surged 65% over the past year. Arcutis is transitioning from development to commercialization, with its ZORYVE eczema cream generating $372.1 million in net product revenue in 2025 (up 123% year-over-year) and achieving positive operating cash flow.

Arcutis Biotherapeutics announced its Q4 and full year 2025 financial results and provided a business update. The company will present at the TD Cowen 46th Annual Health Care Conference on March 2-4, 2026, in Boston. Arcutis also announced that professional golfer Max Homa has joined its 'Free to Be Me' campaign to raise awareness about seborrheic dermatitis treatments.

Arcutis Biotherapeutics reported Q4 2025 net product revenue of $127.5 million for ZORYVE (roflumilast), an 84% increase year-over-year, with full-year 2025 revenue reaching $372.1 million (123% growth). The company achieved positive operating cash flow, raised 2026 guidance to $480-495 million, and reported positive Phase 2 trial data for pediatric atopic dermatitis. The company is expanding its dermatology sales force and assuming direct responsibility for pediatric and primary care commercialization.